Menu
Enrolling by invitation NCT06920095

Progressive Muscle Relaxation Exercises on Sleep, Fatigue, Pain in Lymphoma Patients

No phase Interventional Lymphoma Patients

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Progressive muscle relaxation exercises.
Who it may be relevant to
Registry conditions: Lymphoma Patients. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of Progressive Muscle Relaxation Exercises on Sleep, Fatigue and Pain in Lymphoma Patients

Overview

With regular practice, relaxation has been found to have many benefits such as reducing sensitivity to pain and fatigue, facilitating the transition to sleep, and improving quality of life. Therefore, this study was planned to examine the effects of progressive muscle relaxation exercises applied to lymphoma patients on sleep, fatigue, and pain.

Detailed description

A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.

Interventions

  • Other Progressive muscle relaxation exercises
    A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.

Primary outcome measures

  • Visual Analog Scale [Time frame: Baseline, pre-intervention (Before progressive muscle relaxation exercises applied)]
  • Visual Analog Scale [Time frame: After the intervention (After progressive muscle relaxation exercises applied in week 6)]
  • The Piper Fatigue Scale [Time frame: Baseline, pre-intervention (Before progressive muscle relaxation exercises applied)]
  • The Piper Fatigue Scale [Time frame: After the intervention (After progressive muscle relaxation exercises applied in week 6)]
Secondary outcome measures (2)
  • Pittsburgh Sleep Quality Index (PSQI) [Time frame: Baseline, pre-intervention (Before progressive muscle relaxation exercises applied)]
  • Pittsburgh Sleep Quality Index (PSQI) [Time frame: After the intervention (After progressive muscle relaxation exercises applied in week 6)]

Eligibility criteria

Inclusion criteria

  • Being over 18 years of age
  • Being able to communicate adequately
  • Not having a psychiatric problem
  • Those who are determined by a physician to have no physical obstacle to exercise
  • Individuals who can use technological devices
  • Patients who have had at least 3 cycles

Exclusion criteria

  • Those with communication problems
  • Those with psychiatric problems
  • Patients doing any exercise
  • Individuals with phones that do not have a voice recording feature
  • Individuals with phones that do not have a WhatsApp feature

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

Turkey (Türkiye) · 1 center
  • Istanbul Sabahattin Zaim University, Faculty of Health Sciences, — Küçükçekmece

Publications

  • Loh EW, Shih HF, Lin CK, Huang TW. Effect of progressive muscle relaxation on postoperative pain, fatigue, and vital signs in patients with head and neck cancers: A randomized controlled trial. Patient Educ Couns. 2022 Jul;105(7):2151-2157. doi: 10.1016/j.pec.2021.10.034. Epub 2021 Nov 3. PMID 34785078
  • Tan L, Fang P, Cui J, Yu H, Yu L. Effects of progressive muscle relaxation on health-related outcomes in cancer patients: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2022 Nov;49:101676. doi: 10.1016/j.ctcp.2022.101676. Epub 2022 Oct 31. PMID 36332326

Identifiers

NCT: NCT06920095 · 2025/01-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗